We are a biologics company committed to translating innovative science into medicines that transform the lives of patients with various diseases.
Vitro Biopharma is a clinical-stage biotechnology company focused on developing Wharton's jelly-derived cell therapies and targeting new treatments for millions of patients with rare and broad indications. Our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.
There are multiple characteristics of umbilical cord MSCs significantly superior to those derived from adipose, bone marrow or placental tissues. Umbilical cord MSCs have superior potency by mitochondrial and immunosuppression measurement and are the youngest adult stem cells, free from age related issues, prior medical conditions and genetics. AlloRx® Stem Cells are ethically sourced and derived from the Wharton’s Jelly of the umbilical cord. Strict screening of the donor's medical & social history is evaluated as well as rigorous testing of the donor's tissue is preformed prior to accepting cords.
Derived from the most potent stem cells measured by purity and potency, Wharton’s jelly of the umbilical cord, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our lead product candidate, AlloRx® has been used internationally to treat a variety of patients with autoimmune and inflammatory diseases, such as COPD, osteoarthritis, multiple sclerosis, Pitt-Hopkin's, Alzheimer’s, and lupus.
Vitro Biopharma has a significant cost advantage within our patent pending, proprietary and scalable manufacturing process.
Modern cell therapy and stem cell technology are rapidly evolving and hold promise to revolutionize medicine by allowing regeneration of any type of cell within the human body. We believe our 30 years of drug discovery and development, supplying research products to world-class institutions and pharmaceutical companies, has enabled us to identify and advance multiple product candidates from preclinical studies into clinical trials. Here are some of the remarkable people we have worked with.